A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2014
At a glance
- Drugs KRP 104 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors ActivX Biosciences
- 10 Jun 2017 Biomarkers information updated
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.